Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target
Benzinga Newsdesk 3 months ago
NewsUpgradesAnalyst RatingsPrice Target
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.